



[Print this Page for Your Records](#)

[Close Window](#)

Control/Tracking Number: 2024-A-350-ACTRIMS

Activity: Abstract

Current Date/Time: 11/7/2023 3:03:27 AM

A Prospective Data Collection to Evaluate Utility and Added Value of Serum NfL in Multiple Sclerosis: First Interim Insights from NeofiLos

Author Block: K. Akguen¹, U. Schulze-Topphoff², K. Schuh², I. Schwab Sauerbeck², T. Ziemssen¹;

¹Center of Clinical Neuroscience, Dresden, GERMANY, ²Novartis Germany IMI, Nuernberg, GERMANY.

Abstract:

Background: Neuroaxonal damage results in release of neurofilaments such as neurofilament light chain (NfL) with elevated NfL potentially indicating RMS disease activity^{[1][2][3]}. Elevated NfL levels may reveal "subclinical" disease before lesions appear on MRI or clinical symptoms appear^[4]. Measuring sNfL may help elucidate subclinical disease activity with prognostic value for future disease activity and potentially contribute to optimized decision making.

[1] Thebault S et al. *Mult Scler.* 2022;28(10):1491-1497. [2] Dietmann AS et al. *J Neurol.* 2023;270(3):1416-1429. [3] Kuhle J et al. *Mult Scler.* 2020;26(13):1691-1699. [4] Akgün K et al. *Neurol Neuroimmunol Neuroinflamm.* 2019;6(3):e555.

Objectives: NeofiLos enables office-based centers to access sNfL testing aiming to investigate utility of serial sNfL measurements in clinical routine in Germany.

Methods: NeofiLos is an ongoing prospective data collection at ~80 office-based neurologists assessing the utility of sNfL from physician's perspective in 500 RMS patients treated with ofatumumab or other approved first-line disease modifying therapies. sNfL will be measured at baseline followed by quarterly interval up to 5x per patient. Values embedded into scientific context using patient demographics are reported to neurologists who evaluate sNfL value and assess implementation of sNfL into clinical routine via questionnaires.

Results: Data will provide insights on general perception of sNfL at baseline including benefits and gaps based on current knowledge and experience with sNfL. An analysis of questionnaires will shed light on sNfL value from physicians perspective for future patient care including practical aspects of how, under which conditions, and with what frequency sNfL shall be used. Data will depict details on accessibility and reimbursement as prerequisites for implementation in daily practice. Data are in line with abstract #351.

Conclusions: This is the 1st physician reported data on implementation of sNfL in routine medical care setting highlighting the importance and added benefit of sNfL as additional parameter in MS patient management allowing early gap identification for sNfL use in MS.

Additional (Complete):

Are you a Young Investigator? Young Investigators are students/trainees OR professionals who have obtained an advanced degree (M.D. or Ph.D.) within seven years of the time of abstract submission.: No

Highly rated submissions will be considered for an oral presentation. If selected, are you willing to make an oral presentation?: Yes

Are you a National MS Society Fellow?: No

Are you a Canadian MS Society Fellow?: No

NAIMS: No

IMSVISUAL: No

iWiMS: No

LACTRIMS: No

Would you like this abstract considered for oral presentation in partner programs, workshops, or symposia associated with the ACTRIMS Forum?: No

Keyword (Complete): Biomarkers

Status: Complete

Feedback

